Advertisement

Addition of Bortezomib to Chemotherapy in Newly Diagnosed T-Cell Lymphoblastic Lymphoma (T-LL) and T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Posted: 03/15/2022 | By: Matthew Stenger

Question 1 of 5

Four-year event-free survival with vs without bortezomib was:

Choose 1

A
83.8% vs 80.1% in the T-ALL population
B
86.4% vs 76.5% in the T-LL population
C
82.9% vs 81.5% in the total population
D
88.3% vs 85.7% in the T-LL population

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage